# GT Biopharma (GTBP) — News

GTBP · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/gtbp/news

## Recent headlines

- [Cannabis stocks rose in premarket trading, with Green Thumb Industries up 16%, IGC Biosciences gaining 3.93% and Canopy Growth rising 2.77%.](https://www.ainvest.com/news/cannabis-stocks-rose-premarket-trading-green-thumb-industries-16-igc-biosciences-gaining-3-93-canopy-growth-rising-2-77-2610-1) — AInvest Wire, Oct 12, 2026
  Cannabis stocks experienced gains in premarket trading on October 12, 2026, with Green Thumb Industries (GTBIF) rising 16% following a series of recent developments, including the expansion of its retail footprint in Florida and Nevada. The company recently opened its 25th Florida location, RISE…
- [GT Biopharma - Selling stockholders to offer up to 13,502,835 shares of common stock - SEC filing](https://www.ainvest.com/news/gt-biopharma-selling-stockholders-offer-13-502-835-shares-common-stock-sec-filing-2610) — AInvest Wire, Oct 9, 2026
  GT Biopharma, Inc. (NASDAQ: GTBP) has filed a prospectus with the U.S. Securities and Exchange Commission (SEC) under which selling shareholders may offer up to 740,000 shares of the company’s common stock. These shares are issuable upon the exercise of warrants issued in a private placement on May…
- [GT Biopharma - Phase 1 trial with GTB-5550 in solid tumors actively enrolling, update expected Q4 2026](https://www.ainvest.com/news/gt-biopharma-phase-1-trial-gtb-5550-solid-tumors-actively-enrolling-update-expected-q4-2026-2609) — AInvest Wire, Sep 15, 2026
  GT Biopharma Inc. (NASDAQ: GTBP) announced that its Phase 1 clinical trial for GTB-5550, an investigational therapy targeting solid tumors, is currently enrolling participants. The trial aims to evaluate the safety, tolerability, and preliminary efficacy of GTB-5550 in patients with advanced solid…
- [GT Biopharma announces potential new indication for GTB-5550, a B7-H3-targeted natural killer (NK) cell engager, for multiple myeloma](https://www.ainvest.com/news/gt-biopharma-announces-potential-indication-gtb-5550-b7-h3-targeted-natural-killer-nk-cell-engager-multiple-myeloma-2609) — AInvest Wire, Sep 15, 2026
  GT Biopharma has announced that its investigational therapy, GTB-5550, a B7-H3-targeted natural killer (NK) cell engager, may be evaluated for a new indication in the treatment of multiple myeloma. The company is exploring the potential of GTB-5550 to harness the body’s immune system by engaging NK…
- [GT Biopharma - to expand pipeline targets beyond oncology in 2027](https://www.ainvest.com/news/gt-biopharma-expand-pipeline-targets-oncology-2027-2606) — AInvest Wire, Jun 1, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).